Real-world experience with tisagenlecleucel for the treatment of relapsed or refractory diffuse large B-cell lymphoma in Korea.
Saved in:
| Title: | Real-world experience with tisagenlecleucel for the treatment of relapsed or refractory diffuse large B-cell lymphoma in Korea. |
|---|---|
| Authors: | Kim DH; Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea.; Department of Translational Medicine, Seoul National University College of Medicine, Seoul, Korea., Kwon S; Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea.; Department of Translational Medicine, Seoul National University College of Medicine, Seoul, Korea., Cha S; Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea., Öz RS; Department of Internal Medicine, Hacettepe University Hospital, Ankara, Turkiye., Hong J; Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea.; Biomedical Research Institute, Seoul National University Hospital, Seoul, Korea.; Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea., Shin DY; Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea.; Biomedical Research Institute, Seoul National University Hospital, Seoul, Korea.; Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea., Koh Y; Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea.; Biomedical Research Institute, Seoul National University Hospital, Seoul, Korea.; Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea., Yoon SS; Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea.; Biomedical Research Institute, Seoul National University Hospital, Seoul, Korea.; Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea., Byun JM; Department of Internal Medicine, Seoul National University Hospital, 101 Daehak-ro, Jongno-gu, Seoul 03080, KoreaBiomedical Research Institute, Seoul National University Hospital, Seoul, Korea Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea. |
| Source: | Therapeutic advances in hematology [Ther Adv Hematol] 2025 Dec 22; Vol. 16, pp. 20406207251406461. Date of Electronic Publication: 2025 Dec 22 (Print Publication: 2025). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Sage Country of Publication: England NLM ID: 101549589 Publication Model: eCollection Cited Medium: Print ISSN: 2040-6207 (Print) Linking ISSN: 20406207 NLM ISO Abbreviation: Ther Adv Hematol Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| FullText | Links: – Type: pdflink Text: Availability: 1 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 41445759 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Real-world experience with tisagenlecleucel for the treatment of relapsed or refractory diffuse large B-cell lymphoma in Korea. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Kim+DH%22">Kim DH</searchLink>; Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea.; Department of Translational Medicine, Seoul National University College of Medicine, Seoul, Korea.<br /><searchLink fieldCode="AU" term="%22Kwon+S%22">Kwon S</searchLink>; Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea.; Department of Translational Medicine, Seoul National University College of Medicine, Seoul, Korea.<br /><searchLink fieldCode="AU" term="%22Cha+S%22">Cha S</searchLink>; Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea.<br /><searchLink fieldCode="AU" term="%22Öz+RS%22">Öz RS</searchLink>; Department of Internal Medicine, Hacettepe University Hospital, Ankara, Turkiye.<br /><searchLink fieldCode="AU" term="%22Hong+J%22">Hong J</searchLink>; Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea.; Biomedical Research Institute, Seoul National University Hospital, Seoul, Korea.; Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea.<br /><searchLink fieldCode="AU" term="%22Shin+DY%22">Shin DY</searchLink>; Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea.; Biomedical Research Institute, Seoul National University Hospital, Seoul, Korea.; Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea.<br /><searchLink fieldCode="AU" term="%22Koh+Y%22">Koh Y</searchLink>; Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea.; Biomedical Research Institute, Seoul National University Hospital, Seoul, Korea.; Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea.<br /><searchLink fieldCode="AU" term="%22Yoon+SS%22">Yoon SS</searchLink>; Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea.; Biomedical Research Institute, Seoul National University Hospital, Seoul, Korea.; Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea.<br /><searchLink fieldCode="AU" term="%22Byun+JM%22">Byun JM</searchLink>; Department of Internal Medicine, Seoul National University Hospital, 101 Daehak-ro, Jongno-gu, Seoul 03080, KoreaBiomedical Research Institute, Seoul National University Hospital, Seoul, Korea Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22101549589%22">Therapeutic advances in hematology</searchLink> [Ther Adv Hematol] 2025 Dec 22; Vol. 16, pp. 20406207251406461. <i>Date of Electronic Publication: </i>2025 Dec 22 (<i>Print Publication: </i>2025). – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Sage%22">Sage </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>101549589 <i>Publication Model: </i>eCollection <i>Cited Medium: </i>Print <i>ISSN: </i>2040-6207 (Print) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2220406207%22">20406207 </searchLink><i>NLM ISO Abbreviation: </i>Ther Adv Hematol <i>Subsets: </i>PubMed not MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41445759 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1177/20406207251406461 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 20406207251406461 Titles: – TitleFull: Real-world experience with tisagenlecleucel for the treatment of relapsed or refractory diffuse large B-cell lymphoma in Korea. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Kim DH – PersonEntity: Name: NameFull: Kwon S – PersonEntity: Name: NameFull: Cha S – PersonEntity: Name: NameFull: Öz RS – PersonEntity: Name: NameFull: Hong J – PersonEntity: Name: NameFull: Shin DY – PersonEntity: Name: NameFull: Koh Y – PersonEntity: Name: NameFull: Yoon SS – PersonEntity: Name: NameFull: Byun JM IsPartOfRelationships: – BibEntity: Dates: – D: 22 M: 12 Text: 2025 Dec 22 Type: published Y: 2025 Identifiers: – Type: issn-print Value: 2040-6207 Numbering: – Type: volume Value: 16 Titles: – TitleFull: Therapeutic advances in hematology Type: main |
| ResultId | 1 |